JUN TERUYA to Thrombosis
This is a "connection" page, showing publications JUN TERUYA has written about Thrombosis.
Connection Strength
2.534
-
Bivalirudin or Unfractionated Heparin for Anticoagulation in Pediatric Patients on Continuous Flow Ventricular Assist Device Support: Single-Center Retrospective Cohort Study. Pediatr Crit Care Med. 2022 10 01; 23(10):e465-e475.
Score: 0.566
-
Hemostatic Management of Extracorporeal Circuits Including Cardiopulmonary Bypass and Extracorporeal Membrane Oxygenation. Semin Thromb Hemost. 2020 Feb; 46(1):62-72.
Score: 0.476
-
Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation. Semin Thromb Hemost. 2018 Feb; 44(1):20-29.
Score: 0.407
-
Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO. J Extra Corpor Technol. 2011 Jun; 43(2):64-9.
Score: 0.264
-
Retrospective Comparison of Recombinant Activated Factor VII Versus 4-Factor Prothrombin Complex Concentrate in Cardiac Surgical Patients. J Cardiothorac Vasc Anesth. 2024 Feb; 38(2):388-393.
Score: 0.157
-
Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee. J Thromb Haemost. 2023 01; 21(1):164-174.
Score: 0.147
-
Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH. J Thromb Haemost. 2022 07; 20(7):1735-1743.
Score: 0.141
-
Tortuosity-powered microfluidic device for assessment of thrombosis and antithrombotic therapy in whole blood. Sci Rep. 2020 04 01; 10(1):5742.
Score: 0.122
-
Free hemoglobin increases von Willebrand factor-mediated platelet adhesion in vitro: implications for circulatory devices. Blood. 2015 Nov 12; 126(20):2338-41.
Score: 0.088
-
Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2014 Jun; 15(5):e198-205.
Score: 0.081
-
Practice guidelines for reversal of new and old anticoagulants. Dis Mon. 2012 Aug; 58(8):448-61.
Score: 0.071
-
Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther. 2009 May; 20(5):479-85.
Score: 0.014